The partnership is set to transform infant care
by providing virtual telehealth services to caregivers, increasing
access to innovative medical-grade monitoring.
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer
of smart infant monitoring, announces a strategic partnership with
Wheel, an industry leader in providing virtual patient-centric
care. Through this partnership, Wheel clinicians will provide
caregivers of infants with timely prescriptions for BabySat™,
Owlet’s FDA-cleared infant pulse oximeter, ushering in a new era of
digital healthcare solutions for families.
Annually, more than 450,000 babies transition home from the
neonatal intensive care unit (NICU)1. Further, every year in the
United States, Congenital Heart Disease (CHD) affects 40,000
babies2 and an estimated 58,000-80,000 children under five with
respiratory syncytial virus (RSV) require hospitalization3.
BabySat, featuring Owlet’s signature wire-free sock design,
empowers caregivers to more effectively monitor their baby’s health
and collaborate with healthcare providers to ensure optimal
care.
“Home monitoring plays a pivotal role in safeguarding at-risk
infants by improving access to health services,” said Jim Fidacaro,
Owlet Senior Vice President and General Manager of Healthcare.
“Owlet, in partnership with Wheel, can now enable parents to obtain
prescriptions for BabySat directly via Wheel’s online portal and
network of physicians. With a prescription, caregivers will then be
able to order BabySat at little to no cost with insurance
reimbursement.”
The BabySat virtual telehealth services platform, managed and
powered by Wheel, also integrates with durable medical equipment
(DME) suppliers who accept and can bill for the product through
many insurance providers, who may offer up to 100% reimbursement
for BabySat. This new, streamlined process makes advanced
monitoring even more accessible by significantly reducing the
effort and time needed to secure BabySat and get reimbursed through
insurance or HSA/FSA.
“We’re thrilled to announce our strategic partnership with
Owlet, a leader in smart infant monitoring. This collaboration
marks a significant milestone in our mission to expand healthcare
access and simplify care delivery for all Americans — especially
for growing families,” said Wheel CEO, Michelle Davey. “Wheel’s
virtual care platform helps streamline access to home monitoring,
making Owlet’s BabySat pulse oximeter more convenient for new
parents than ever before.”
Detailed information on BabySat and the telehealth services
process are available at www.owletcare.com. These partnerships
reflect Owlet's commitment to providing accessible, high-quality
care for infants and their families.
About Owlet, Inc.
Owlet was founded by a team of parents in 2012. Owlet’s mission
is to empower parents with the right information at the right time,
to give them more peace of mind and help them find more joy in the
journey of parenting. Owlet’s digital parenting platform aims to
give parents real-time data and insights to help parents feel
calmer and more confident. Owlet believes that every parent
deserves peace of mind and the opportunity to feel their
well-rested best. Owlet also believes that every child deserves to
live a long, happy, and healthy life, and is working to develop
products to help further that belief. To learn more, visit
www.owletcare.com.
About Wheel
Wheel is evolving the traditional care ecosystem by equipping
the nation's most innovative companies with a premier platform to
deliver high-quality virtual care at scale. We offer proven
strategies and cutting-edge technologies to foster consumer
engagement, build brand loyalty, and maximize return on investment.
Wheel solutions include configurable virtual care programs, an
intuitive consumer interface, and access to a nationwide network of
board-certified clinicians. Discover how Wheel is transforming the
future of healthcare by visiting www.wheel.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(the “Reform Act”). All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements, including, without
limitation, statements regarding the Company’s ability to dispense
BabySat through Wheel’s telehealth services platform, the BabySat’s
reimbursement under insurance plans and parents’ and caregivers’
access to the BabySat products through those plans. In some cases,
you can identify forward-looking statements by terms such as
“estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,”
“intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,”
the negation thereof, or similar expressions, although not all
forward-looking statements contain these identifying words.
Forward-looking statements are based on the Company’s expectations
at the time such statements are made, speak only as of the dates
they are made and are susceptible to a number of risks,
uncertainties and other factors. For all such forward-looking
statements, the Company claims the protection of the safe harbor
for forward-looking statements contained in the Reform Act. The
Company’s actual results, performance or achievements may differ
materially from any future results, performance or achievements
expressed or implied by our forward-looking statements. Many
important factors could affect the Company’s future results and
cause those results to differ materially from those expressed in or
implied by the Company’s forward-looking statements. Such factors
include, but are not limited to, (i) the availability of, adoption
and reimbursement success of BabySat within new healthcare payment
programs, (ii) the regulatory pathway for Owlet’s products,
including submissions to, actions taken by and decisions and
responses from regulators, such as the FDA and similar regulators
outside of the United States, as well as Owlet’s ability to obtain
and maintain regulatory approval or certification for our products
and other regulatory requirements and legal proceedings; (iii)
Owlet’s competition and the Company’s ability to profitably grow
and manage growth; (iv) the Company’s ability to enhance future
operating and financial results or obtain additional financing to
continue as a going concern; (v) Owlet’s ability to obtain
additional financing in the future, as well risks associated with
the Company’s current loan and debt agreements, including
compliance with debt covenants, restrictions on the Company’s
access to capital, the impact of the Company’s overall debt levels
and the Company’s ability to generate sufficient future cash flows
to meet Owlet’s debt service obligations and operate Owlet’s
business; (vi) the ability of Owlet to implement strategic
initiatives, reduce costs, grow revenues, develop and launch new
products, innovate and enhance existing products, meet customer
demands and adapt to changes in consumer preferences and retail
trends; (vii) Owlet’s ability to acquire, defend and protect its
intellectual property and satisfy regulatory requirements,
including but not limited to requirements concerning privacy and
data protection, breaches and loss, as well as other risks
associated with Owlet’s digital platforms and technologies; (viii)
Owlet’s ability to maintain relationships with customers,
manufacturers and suppliers and retain Owlet’s management and key
employees; (ix) Owlet’s ability to upgrade and maintain its
information technology systems; (x) changes in applicable laws or
regulations; (xi) the impact of and disruption to Owlet’s business,
financial condition, operations, supply chain and logistics due to
economic and other conditions beyond the Company’s control, such as
health epidemics or pandemics, macro-economic uncertainties, social
unrest, hostilities, natural disasters or other catastrophic
events; (xii) the possibility that Owlet may be adversely affected
by other economic, business, regulatory, competitive or other
factors, such as changes in discretionary consumer spending and
consumer preferences; and (xiii) other risks and uncertainties set
forth in the Company’s other releases, public statements and
filings with the U.S. Securities and Exchange Commission (“SEC”),
including those identified in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023, and as any such factors may be updated from time
to time in the Company’s other filings with the SEC. All such
forward-looking statements attributable to the Company or any
person acting on the Company’s behalf are expressly qualified in
their entirety by the cautionary statements contained or referred
to above. Moreover, the Company operates in an evolving
environment. New risk factors and uncertainties may emerge from
time to time, and factors that the Company currently deems
immaterial may become material, and it is impossible for the
Company to predict such events or how they may affect Owlet. Except
as required by law, the Company assumes no obligation to update any
forward-looking statements after the date of this press release,
whether because of new information, future events or otherwise,
although Owlet may do so from time to time. The Company does not
endorse any projections regarding future performance that may be
made by third parties.
References:
-
https://publications.aap.org/pediatrics/article/144/2_MeetingAbstract/687/3792/The-Association-of-Transition-to-Home-and-Hospital?autologincheck=redirected
- https://www.cdc.gov/ncbddd/heartdefects/data.html
-
https://www.cdc.gov/rsv/high-risk/infants-young-children.html#:~:text=Each%20year%20in%20the%20United,those%206%20months%20and%20younger
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425179815/en/
Owlet Media Contacts: pr@owletcare.com
owlet@diffusionpr.com
Owlet Health Contact: healthcareteam@owletcare.com
Wheel Media Contact: press@wheel.com
Grafico Azioni Sandbridge Aquisition (NYSE:OWLT)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Sandbridge Aquisition (NYSE:OWLT)
Storico
Da Gen 2024 a Gen 2025
